OSL oncosil medical ltd

Ann: Positive Regulatory Updates, page-45

  1. 651 Posts.
    lightbulb Created with Sketch. 173
    https://ascopubs.org/doi/full/10.1200/JCO.18.01295
    Vol. 37, No. 13, May 1, 2019 pages 1062-9

    What an interesting read. The control arm of METASTATIC pancreatic cancer using FOLFIRINOX had a median survival of 14.4 months.

    Not looking for Oncosil's argument that median survival would've been 9-11 months for LOCAL pancreatic cancer had they incorporated a control arm in the trial design.

    I wonder if the tome Oncosil wrote included that one.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.11
Change
0.025(2.30%)
Mkt cap ! $20.89M
Open High Low Value Volume
$1.09 $1.11 $1.09 $26.73K 24.35K

Buyers (Bids)

No. Vol. Price($)
1 6807 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.12 6617 1
View Market Depth
Last trade - 16.10pm 07/08/2025 (20 minute delay) ?
OSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.